Infection Resistant to Multiple Drugs Clinical Trial
Official title:
Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)
Multi-Drug resistant pathogens (MDR) are reported worldwide with increasing incidence,
especially in intensive care settings.
One of the drugs which are effective against MDRs, is colistin (polymyxin E). This agent has
been reintroduced in response to the increase of MDR pathogens and might be used more often
in the future. Data on safety regarding the most important side effects are not sufficiently
available. l This study evaluates the toxicity in patients who receive aerosolized colistin.
There is growing evidence that patients in the ICU setting have a special risk profile for
consecutive colonization and possible infection due to MDR pathogens.
One therapy option is the use of inhalative colistin, as this agent has been demonstrated to
be effective against these pathogens. Data on pharmacodynamics or - kinetics are transferred
from older studies or from other patient populations. For patients with pulmonary
colonization or infection due to an MDR pathogen the systemic resorption of the drug is not
known, consequently systemic side effects including kidney or neural damage are not
predictable.
This study focus on patients with inhalative colistin therapy and uses therapeutic drug
monitoring to determine the rate of systemic resorption of colistin. For the evaluation of
neurotoxicity function of peripheral nerves (neve conduction velocity) and of the eighth
cranial nerve is monitored. Nephrotoxicity is estimated by creatinine level (-clearance) and
the RIFLE criteria.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02806141 -
Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates
|
Phase 3 | |
Active, not recruiting |
NCT01208519 -
SATURN 04 Nosocomial Acquisition Study
|
N/A |